Objective To evaluate the short-term efficacy and predictive index of anlotinib hydrochloride capsule on advanced NSCLC patients.

Methods We retrospectively reviewed the clinical characteristics of 83 patients with non-small cell lung cancer who had received the second-line chemotherapy. Kaplan-Meier method was used to calculate the rate of PFS. Log rank method was used for statistical test of survival curve. Cox regression model was used to analyze the influence of multiple factors on progress free survival (PFS). ROC curve was used analyze the prognostic value of multiple indicators.

Results Among 83 patients with advanced NSCLC, there were 0 case of CR, 10 cases of PR, 56 cases of SD and 17 cases of PD. The side-effect could be controlled. The ORR and DCR were 12.0% and 79.5%, respectively. The mPFS was 4.43 months. In univariate analysis, the patients with ECOG score≥2, hypoalbuminemia, pleural effusion, elevated GGT and CYFRA21-1, decreased Pct and vascular tumor embolus had shorter PFS. Multivariable Cox regression analysis showed ECOG score, hypoalbuminemia, pleural effusion, CYFRA21-1 and vascular tumor embolus were independent prognostic factors.

Conclusion For patients with non-small cell lung cancer progressing after the second-line treatment, the third-line treatment with anlotinib is safe and effective. Patients with ECOG score≥2, increased CYFRA21-1, hypoalbuminemia, pleural effusion and vascular tumor emboli have a poor prognosis. CYFRA21-1 has relatively high predictive value.